The alarming trend in the number of observed mutations on SARS-COV-2, the virus causing COVID-19, continues apace. We continue to see mutations on these variants that could change the stability of the spike protein and its binding potential to antibodies, thus allowing for more infectivity and immune evasion respectively.
The number of mutated sequences and overall mutation count continues to increase as expected. This is cause for concern as sequence variants may not have the same efficacy as the previously characterized sequences against vaccines and therapeutics:
FLOVID-20 targets a subset of the nucleocapsid protein that has not been shown to mutate at a high degree. This region is conserved through evolution of coronaviruses due to its roles in replication of the viral genome. FLOVID-20 is able to accomplish this by specifically stimulating T-cells that can target these highly expressed and immunogenic conserved internal proteins. This is in stark contrast to current antibody vaccines and therapeutics that are restricted to targeting a region of the spike protein shown to mutate and evade antibodies in recent research.